abrdn plc Purchases New Holdings in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS)

abrdn plc purchased a new stake in shares of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 552,572 shares of the biopharmaceutical company’s stock, valued at approximately $6,006,000.

Several other large investors have also recently bought and sold shares of MRNS. BluePath Capital Management LLC acquired a new position in Marinus Pharmaceuticals during the third quarter valued at approximately $38,000. China Universal Asset Management Co. Ltd. raised its stake in Marinus Pharmaceuticals by 383.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,307 shares of the biopharmaceutical company’s stock valued at $69,000 after buying an additional 5,003 shares during the period. SG Americas Securities LLC bought a new stake in Marinus Pharmaceuticals in the fourth quarter valued at approximately $134,000. Sherbrooke Park Advisers LLC bought a new stake in Marinus Pharmaceuticals in the third quarter valued at approximately $141,000. Finally, Acuta Capital Partners LLC bought a new stake in Marinus Pharmaceuticals in the third quarter valued at approximately $157,000. 98.80% of the stock is owned by institutional investors and hedge funds.

Marinus Pharmaceuticals Price Performance

Shares of NASDAQ MRNS opened at $1.41 on Friday. The business’s 50 day moving average is $7.51 and its 200-day moving average is $8.15. Marinus Pharmaceuticals, Inc. has a 1-year low of $1.11 and a 1-year high of $11.26. The company has a current ratio of 4.07, a quick ratio of 4.01 and a debt-to-equity ratio of 5.68. The firm has a market cap of $77.18 million, a P/E ratio of -0.53 and a beta of 0.91.

Marinus Pharmaceuticals (NASDAQ:MRNS) last posted its quarterly earnings data on Tuesday, March 5th. The biopharmaceutical company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.10). Marinus Pharmaceuticals had a negative return on equity of 269.75% and a negative net margin of 456.31%. The company had revenue of $7.19 million for the quarter, compared to the consensus estimate of $7.78 million. During the same quarter last year, the business earned ($0.76) EPS. Equities research analysts predict that Marinus Pharmaceuticals, Inc. will post -2.23 earnings per share for the current year.

Analysts Set New Price Targets

MRNS has been the topic of several research analyst reports. Cantor Fitzgerald restated an “overweight” rating and issued a $28.00 price objective on shares of Marinus Pharmaceuticals in a research note on Wednesday, April 10th. Robert W. Baird restated a “neutral” rating on shares of Marinus Pharmaceuticals in a research note on Tuesday, April 16th. StockNews.com lowered Marinus Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, March 6th. Oppenheimer reiterated a “market perform” rating and set a $9.00 target price on shares of Marinus Pharmaceuticals in a research note on Thursday, March 7th. Finally, HC Wainwright reiterated a “buy” rating and set a $27.00 target price on shares of Marinus Pharmaceuticals in a research note on Tuesday, April 16th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $16.07.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.